EQL Pharma AB (publ)

OM:EQL 株式レポート

時価総額：SEK 738.2m

EQL Pharma 将来の成長

Future 基準チェック /66

EQL Pharma利益と収益がそれぞれ年間101%と21.9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に25.2% 71.5%なると予測されています。

主要情報

101.0%

収益成長率

71.54%

EPS成長率

Healthcare 収益成長17.0%
収益成長率21.9%
将来の株主資本利益率25.17%
アナリストカバレッジ

Low

最終更新日14 Aug 2026

今後の成長に関する最新情報

分析記事 • May 13

EQL Pharma AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

There's been a major selloff in EQL Pharma AB (publ) ( STO:EQL ) shares in the week since it released its yearly...

Recent updates

ナラティブ更新 • Jun 17

EQL: European Rollout And New UTI Therapy Will Drive Future Upside

Analysts have kept their SEK price target for EQL Pharma broadly unchanged, with only minimal adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E. This reflects a largely steady view of the stock's valuation profile.
ナラティブ更新 • Jun 02

EQL: European Rollout And Supply Chain Improvements Will Drive Future Upside

Analysts have reduced their fair value estimate for EQL Pharma’s shares from SEK 75 to SEK 50, citing updates to their models that reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma issued earnings guidance for 2026/27, with sales growth below its long term 30% target and an EBITDA margin of 10%, reflecting impacts from supply shortages and one off effects.
分析記事 • May 14

This Analyst Just Downgraded Their EQL Pharma AB (publ) (STO:EQL) EPS Forecasts

The analyst covering EQL Pharma AB (publ) ( STO:EQL ) delivered a dose of negativity to shareholders today, by making a...
分析記事 • May 13

EQL Pharma AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models

There's been a major selloff in EQL Pharma AB (publ) ( STO:EQL ) shares in the week since it released its yearly...
ナラティブ更新 • Apr 23

EQL: Italian Approval And New Market Entry Will Support Future Upside Potential

Analysts have adjusted their price target on EQL Pharma to SEK 75 from SEK 80, citing updated assumptions for revenue growth, profit margins and future P/E. These changes point to a slightly more conservative outlook on the shares.
ナラティブ更新 • Apr 09

EQL: Italian Market Entry And Steady Assumptions Will Support Future Upside Potential

Analysts have maintained their SEK price target for EQL Pharma at SEK 80.00, citing consistent assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News EQL's key product Mellozzan, which contains melatonin, has received Marketing Authorization approval from the Italian medicines agency AIFA for use in Italy, through licensing partner Italfarmaco S.p.A. (Key Developments) Mellozzan is indicated for children with ADHD who have sleep difficulties where sleep hygiene measures have not worked, and for short term treatment of jet lag in adults.
ナラティブ更新 • Mar 26

EQL: Long Term Incentive Program Will Support Strong Future Upside Potential

Analysts keep their SEK 80.00 fair value estimate for EQL Pharma unchanged, reflecting steady assumptions on discount rate, revenue growth, profit margin and future P/E, with no new Street research prompting a shift in the target. What's in the News A special or extraordinary shareholders meeting is scheduled for February 3, 2026, at 13:00 W.
ナラティブ更新 • Mar 11

EQL: Long Term Incentive Program Will Support Strong Future Upside Potential

Analysts have kept their price target for EQL Pharma steady at SEK 80. This reflects unchanged views on fair value, discount rate, growth and margin assumptions.
ナラティブ更新 • Feb 24

EQL: Leadership Restructuring And Incentive Plan Will Support Long Term Outlook

Analysts have kept their SEK price target for EQL Pharma unchanged at SEK 80. This reflects stable assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E.
ナラティブ更新 • Feb 10

EQL: German UTI Prophylaxis Approval Will Support Stronger Long Term Outlook

Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00. They explain the steady target by slightly different views on discount rate, revenue growth, profit margin and future P/E assumptions rather than any single strong new data point.
ナラティブ更新 • Jan 27

EQL: German UTI Prophylaxis Launch Will Support Bullish Outlook

Analysts have kept their fair value estimate for EQL Pharma unchanged at SEK 80.00 per share, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News EQL Pharma has called a special or extraordinary shareholders meeting for February 3, 2026, at 13:00 W.
ナラティブ更新 • Jan 12

EQL: Future UTI Prophylaxis Launch In Germany Will Drive Upside

Analysts have maintained their price target on EQL Pharma at SEK 80.00, citing consistent assumptions for the discount rate, revenue growth, profit margin and future P/E that support keeping the previous fair value assessment unchanged. What's in the News EQL Pharma has called a special/extraordinary shareholders meeting for February 3, 2026, at 13:00 W.
ナラティブ更新 • Dec 23

EQL: Future UTI Prophylaxis Launch Will Drive Strong Upside Potential

Analysts have modestly adjusted their price target on EQL Pharma upward to SEK 80.0 per share from SEK 80.0 per share, citing unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the company’s current fair value assessment. What's in the News EQL Pharma strengthens and reorganizes its finance function, appointing Allan Sylvest Aasberg as new CFO from early April 2026, while current CFO Anna Jönsson becomes Head of Accounting (Key Developments) The new CFO is tasked with optimizing profitability, capital allocation, forecasting, and parts of investor relations to support a more scalable growth platform (Key Developments) Key product methenamine hippurate receives marketing approval in Germany under the EQL brand Cystohipp, the only registered product of its kind in that market, with launch planned for mid 2026 (Key Developments) Cystohipp targets recurrent urinary tract infections as a non antibiotic prophylactic option, addressing growing demand for alternatives that do not drive antibiotic resistance (Key Developments) EQL issues guidance indicating robust top line expansion, forecasting around 30 percent sales growth for 2024/25 and around 15 percent for 2025/26 (Key Developments) Valuation Changes Fair Value: unchanged at SEK 80.0 per share, indicating no revision to the overall equity valuation.
ナラティブ更新 • Dec 09

EQL: New Non-Antibiotic UTI Therapy Will Drive Future Upside

Narrative Update on EQL Pharma Analysts have maintained their price target for EQL Pharma at SEK 80.00. This reflects unchanged assumptions on revenue growth, profitability, and valuation multiples despite recent model refinements.
ナラティブ更新 • Nov 25

EQL: Expanding Market Approvals And New Launches Will Drive Future Upside

Analysts have maintained their price target for EQL Pharma at SEK 80.00. They cite stable fair value estimates supported by slightly improved projections for revenue growth and profit margin.
分析記事 • Nov 15

EQL Pharma's (STO:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Last week's earnings announcement from EQL Pharma AB (publ) ( STO:EQL ) was disappointing to investors, with a sluggish...
ナラティブ更新 • Nov 06

EQL: Expansion Into New Markets Will Drive Upside In Coming Years

Analysts have lowered their price target for EQL Pharma from SEK 90.00 to SEK 80.00. They cite revised expectations for valuation and a slightly higher discount rate, despite improved forecasts for revenue growth and profit margin.
分析記事 • Oct 08

EQL Pharma AB (publ) (STO:EQL) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

EQL Pharma AB (publ) ( STO:EQL ) shareholders that were waiting for something to happen have been dealt a blow with a...
分析記事 • Sep 27

Do EQL Pharma's (STO:EQL) Earnings Warrant Your Attention?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
分析記事 • Sep 09

Capital Allocation Trends At EQL Pharma (STO:EQL) Aren't Ideal

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
ナラティブ更新 • Aug 16

EQL Pharma's management aiming for 30% Revenue Growth in 5 Years

2025 Q2 update Solid report. Revenue growth in line with expectations.
分析記事 • May 16

EQL Pharma's (STO:EQL) Earnings Are Of Questionable Quality

EQL Pharma AB (publ) ( STO:EQL ) just reported some strong earnings, and the market reacted accordingly with a healthy...
User avatar
新しいナラティブ • May 11

Pipeline Launches And Global Expansion Will Drive Future Success

Strategic expansions and acquisitions, including Medilink and non-European market entry, are poised to drive significant revenue and profitability growth.
分析記事 • Mar 12

Here's Why EQL Pharma (STO:EQL) Can Manage Its Debt Responsibly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
新しいナラティブ • Feb 22

EQL Pharma aiming for 19% Revenue Growth in 5 Years

Recurring Cash Flow: EQL’s core generic product delivers near‐“infinite” cash flow, thanks to its essential role in healthcare. 
分析記事 • Jan 27

The Trend Of High Returns At EQL Pharma (STO:EQL) Has Us Very Interested

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...
分析記事 • Dec 14

EQL Pharma AB (publ)'s (STO:EQL) P/E Is Still On The Mark Following 37% Share Price Bounce

Despite an already strong run, EQL Pharma AB (publ) ( STO:EQL ) shares have been powering on, with a gain of 37% in the...
分析記事 • Nov 27

Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
分析記事 • Oct 29

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

The EQL Pharma AB (publ) ( STO:EQL ) share price has done very well over the last month, posting an excellent gain of...
分析記事 • Aug 22

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

EQL Pharma AB (publ)'s ( STO:EQL ) stock showed strength, with investors undeterred by its weak earnings report. We...
分析記事 • Aug 12

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • Jun 13

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

The EQL Pharma AB (publ) ( NGM:EQL ) share price has done very well over the last month, posting an excellent gain of...

業績と収益の成長予測

OM:EQL - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
3/31/2029800122431261
3/31/202861371-10632
3/31/2027487N/A-37302
6/30/2026432-14-3321N/A
3/31/202643313-3928N/A
12/31/202542629-267-2N/A
9/30/202539930-274-8N/A
6/30/202539843-275-8N/A
3/31/202537443-270-25N/A
12/31/202433835-54-14N/A
9/30/202431631-91-19N/A
6/30/202429126-86-19N/A
3/31/202426423-78-11N/A
12/31/202324622-4719N/A
9/30/202325628-1112N/A
6/30/202327030-183N/A
3/31/202326031728N/A
12/31/2022403331529N/A
9/30/2022440393451N/A
6/30/2022419364163N/A
3/31/2022410322042N/A
12/31/202123319-649N/A
9/30/20211454-2440N/A
6/30/20211172-66-5N/A
3/31/202117910460N/A
12/31/202017217-1028N/A
9/30/202016316-520N/A
6/30/2020157145065N/A
3/31/2020723N/A7N/A
12/31/2019682N/A3N/A
9/30/201958-2N/A14N/A
6/30/201954-2N/A8N/A
3/31/201950-2N/A6N/A
12/31/201842-2N/A10N/A
9/30/2018390N/AN/AN/A
6/30/2018330N/A-3N/A
3/31/201829-1N/A-2N/A
12/31/2017271N/A-4N/A
9/30/2017270N/A-11N/A
6/30/2017230N/A-7N/A
3/31/2017210N/A1N/A
12/31/2016284N/A1N/A
9/30/2016275N/A10N/A
6/30/2016316N/A6N/A
3/31/2016337N/A2N/A
12/31/2015274N/A0N/A
9/30/2015251N/A-9N/A

アナリストによる今後の成長予測

収入対貯蓄率: EQLは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.1% ) よりも高い成長率であると考えられます。

収益対市場: EQL今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: EQL今後 3 年以内に収益を上げることが予想されます。

収益対市場: EQLの収益 ( 21.9% ) Swedish市場 ( -1.3% ) よりも速いペースで成長すると予測されています。

高い収益成長: EQLの収益 ( 21.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EQLの 自己資本利益率 は、3年後には高くなると予測されています ( 25.2 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/20 23:57
終値2026/08/20 00:00
収益2026/06/30
年間収益2026/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

EQL Pharma AB (publ) 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1

アナリスト機関
Erik HultgårdDNB Carnegie Commissioned Research